treatment

10.

Audit of Global Fund grants to Mali reveals significant progress in financial management and quality of services

28 Nov 2017
However, there are problems with drug expiries, stock-outs and delays in the supply chain
3.

Global Fund to benefit from “breakthrough” ARV pricing agreement

3 Oct 2017
State-of-the-art fixed dose combination regimen will cost $75 per patient per year

In what has been hailed as a “breakthrough” and a “game changer,” a pricing agreement between the Bill and Melinda Gates Foundation and two generic drug companies will result in significant savings in the cost of antiretrovirals (ARVs). As a result of the agreement, starting in 2018 a state-of-the-art fixed dose combination ARV regimen will be available in 92 developing nations at a maximum cost of $75 per patient per year.

2.

Zimbabwe’s TB/HIV funding request to the Global Fund: “Not much room to manoeuver”

27 Apr 2017
Group of donors express concern about the process for developing the funding request and the outcome; the CCM responds

As GFO reported a few weeks ago, Zimbabwe submitted a TB/HIV funding request for $629 million in Window 1 of the current funding cycle. The $629 million request consisted of $432 million that was within Zimbabwe’s allocation, and $197 million for a prioritized above-allocation request (PAAR).

7.

Is the Russian Federation willing and able to manage its HIV epidemic?

3 Apr 2017
Neither the government nor CSOs have taken up the services previously supported by the Global Fund

In January 2017, the Ministry of Finance of the Russian Federation rejected a request to allocate $1.2 billion over four years for the response to HIV, citing “a lack of federal funds.” The Ministry of Health had asked for the funds in order to implement the National AIDS Strategy 2017-2020.

10.

OIG audit of Mozambique grants reveals weaknesses in implementation and supply chain management

13 Mar 2017
Mozambique is a difficult operating environment

An audit into grants to Mozambique undertaken by the Office of the Inspector General has concluded that both grant implementation arrangements and supply chain controls and assurance mechanisms “need significant improvement.”

“Needs significant improvement” is the second lowest rating in the OIG’s four tier rating scheme. The four tiers are effective; partially effective; needs significant improvement; and ineffective.

5.

Advocacy for increased domestic funding a success in Ukraine

3 Oct 2016
The Government of Ukraine has committed to changes that will significantly improve the quality and coverage of ARV, MDR-TB, Hepatitis C and OST treatments.

Advocacy for increased domestic funding led by CSOs and PRs, and strongly underpinned by the Global Fund’s conditions put to the government of Ukraine, has achieved outstanding results. Communities, empowered by the Global Fund, have been able to partner with the Ministry of Health.

5.

Is ending AIDS by 2030 a realistic goal?, researchers ask

19 Sep 2016

In an article published in The Lancet, a group of researchers questions whether the goal of ending the AIDS epidemic by 2030 with current prevention approaches is realistic.

4.

AHF and researchers call for more transparency in UNAIDS’ estimates of the numbers of people on ARVs

17 Sep 2016
The Global Burden of Disease 2015 Study produced some results that differ from the UNAIDS’ figures
UNAIDS responds that it is confident its estimates are accurate

The AIDS Healthcare Foundation (AHF), a Los Angeles-based AIDS service and activist organization with a global reach, has called for more transparency and accountability in the way UNAIDS estimates the number of people living with HIV/AIDS who are on life-saving antiretroviral treatment.

10.

Information on regional programs that were awarded funding in August

16 Sep 2016
Four programs were given $25 million

Among the grants approved by the Board in August (see GFO article) were four regional programs which received $25 million. The Board was acting on recommendations of the Technical Review Panel (TRP) and the Grants Approvals Committee (GAC). This article provides a summary of the some of the comments made by the GAC concerning the regional programs.

8.

Funding approved for shortened HIV grant to Uganda

16 Aug 2016
Funds will be used to purchase additional ARVs

On 3 August 2016, the Board approved additional funding of $37 million to ensure that all essential services for a shortened HIV grant to Uganda can be provided through to 31 December 2017. The money will come from the $700 million which the Fund has identified as being available for portfolio optimization. The Board was acting on recommendations of the Technical Review Panel (TRP) and the Grant Approvals Committee (GAC).

Pages

Subscribe to treatment